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Abstract 
 
Objective: Up to 50% of breast cancer survivors prescribed tamoxifen do not take it as 
prescribed for the full duration, which is linked to increased risk of recurrence and mortality. 
This paper tests the feasibility and acceptability of a self-directed psycho-educational 
intervention to support medication taking.  
Design: A single arm pre-post design was used with 33 women with sub-optimal adherence 
to tamoxifen (scores≤24 on the Medication Adherence Rating Scale, range 5-25) taking part 
in the intervention over two to twelve weeks. 
Method: Feasibility was assessed via eligibility, uptake and retention. Questionnaires were 
completed pre- and post- intervention, and qualitative interviews were conducted to assess 
acceptability of the materials.  
Results: Recruitment and uptake were good, with 87% of eligible participants agreeing to 
participate. Two thirds of participants recruited to the study completed the follow-up 
questionnaires (66%). The qualitative interviews showed that the participants found the 
materials acceptable and helpful. Paired samples t-tests showed small improvements in 
adherence over time, as well as improvements in psychosocial targets of the intervention, 
namely; necessity and concern beliefs, personal control, coherence, distress, symptom 
experience and self-efficacy for managing side-effects.  
Conclusions: The intervention appears to be acceptable and feasible in this population and 
has the potential to improve both adherence and quality of life in breast cancer survivors 
prescribed tamoxifen. Larger scale trials are needed however to establish the efficacy of the 
materials. 
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Background  
 
Over one million women worldwide are diagnosed with breast cancer annually (Parkin, Bray, 
Ferlay & Pisani, 2005). As mortality decreases (Narod, Iqbal, & Miller, 2015), increasing 
numbers of survivors of oestrogen receptor positive breast cancer are being prescribed 
adjuvant hormone therapy (HT) such as tamoxifen. Taken for up to ten years, tamoxifen can 
significantly reduce the risk of breast cancer recurrence and mortality (EBCTCG, 1998). 
However, many women prematurely discontinue tamoxifen before the prescribed duration, 
known as non-persistence, or do not take doses as prescribed, known as non-adherence 
(Hershman et al., 2011; Partridge, Wang, Winer & Avorn, 2003). Both non-persistence and 
non-adherence are associated with increased risk of recurrence and mortality (Barron, 
Cahir, Sharp & Bennett, 2013; Hershman et al., 2011).  
 
Despite the high rates and clinical implications of non-adherence, few interventions have 
been developed to improve adherence to tamoxifen. A series of education-based 
interventions have been conducted with other HTs, but none have shown significant 
differences in adherence between the intervention and control groups (Hadji et al., 2013; 
Neven et al., 2014; Yu et al., 2012; Ziller et al., 2013). However, higher satisfaction with 
information received and improvements in knowledge have been shown (Bourmaud et al., 
2016; Heisig et al., 2015). 
 
The current intervention was developed to address the need for more effective 
interventions supporting tamoxifen adherence. It took the form of a self-directed paper-
based booklet developed in line with the precepts of cognitive behavioural therapy (CBT) 
and behaviour change theory to modify key beliefs about breast cancer recurrence and 
tamoxifen, manage side-effects and increase perceived behavioural control (PBC) over 
medication taking.  
 
Content development was rigorous (Moon, 2017) and followed and Intervention Mapping 
approach based on empirical evidence and two theories of health behaviour; the Common-
Sense Model of illness (Leventhal & Ian, 2012) and the Theory of Planned Behaviour (Ajzen, 
1991) which increases the likelihood  of successful intervention (Haynes, McDonald, Garg & 
Montague, 2002). The intervention also aimed to overcome some of the limitations of 
previous interventions by focusing specifically on women demonstrating sub-optimal 
adherence (Ekinci et al., 2018) and addressing the distinct concepts and unique 
determinants of both intentional and unintentional non-adherence (Moon, Moss-Morris, 
Hunter & Hughes, 2017b; Wouters et al., 2014). 
 
Intentional non-adherence here refers to the deliberate decision not to take medication, 
whereas unintentional non-adherence refers to forgetting, or lacking the capacity or 
resources to take medication correctly (Clifford et al., 2008). By directly targeting known 
determinants of tamoxifen non-adherence through a self-management programme, this 
intervention has the potential to be widely implemented and to improve clinical and 
psychosocial outcomes.  
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The current study aimed to assess the feasibility and acceptability of the intervention 
materials, prior to testing in a larger randomised controlled trial, in line with UK Medical 
Research Council guidance on developing complex interventions (Craig et al., 2008). 
 
The primary objectives of the study were to assess i) the feasibility and ii) acceptability of 
the intervention.  Secondary objectives were to calculate the effect size of any changes in 
adherence or any psychosocial variables associated with adherence that were targeted in 
the intervention.   
 
Methods  
 
Design  
 
An exploratory single arm pre-post design was used with all participants allocated to the 
intervention condition. The intervention was expected to last 4-6 weeks. Full National 
Health Service (NHS) Research Ethics Committee (REC) and Health Research Authority (HRA) 
approval was granted (REC Ref: 16/LO/1205). 
 
Participants  
 
Eligible patients were female, ≥18 years old, had a diagnosis of primary breast cancer, had 
been prescribed adjuvant tamoxifen and had suboptimal levels of adherence, as evidenced 
by scoring <25 on the Medication Adherence Rating Scale (MARS; Horne, Hankins, & Jenkins, 
2001). Participants had to be able to consent for themselves and read and speak English. 
Exclusion criteria were a diagnosis of secondary breast cancer, being on a prescribed course 
of tamoxifen due to end within the next 4-6 weeks, or receiving a diagnosis of depression in 
the past year.  
 
Recruitment  
 
Recruitment took place over six-months using convenience sampling. Twenty-six eligible 
women were approached through breast clinics at four NHS trusts across England, where 
they were identified by clinic staff, provided with study information and completed a 
screening questionnaire. Invitations were sent to 99 participants from a database of women 
who had consented to being contacted about future research. These participants were 
screened based on information they provided as part of a previous study. Finally, adverts 
were placed on Facebook groups and 7 interested patients contacted the research team to 
be screened for eligibility. A total of 132 women were approached. All participants provided 
informed consent.   
 
Procedure  
 
Participants completed a baseline questionnaire with reminders sent after one week if not 
completed. After completing the baseline questionnaire, women were sent the intervention 
booklets and asked to notify the researcher when they had completed the intervention 
materials. They then completed the follow-up questionnaire and were invited to be 
interviewed about their experiences of the intervention. Semi-structured interviews were 
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conducted via telephone for approximately twenty minutes.  Interviews were conducted by 
an independent researcher who was not involved in the intervention development or 
delivery.  
 
Outcome measurements  
 
Primary outcomes  
 
Feasibility of delivering the intervention was assessed by:  
 
• The percentage of eligible women within the recruitment centres. 
• The percentage of eligible women agreeing to participate (uptake). 
• The percentage of women remaining until the close of the study (retention). 
 
Acceptability was assessed using semi-structured interviews with women who took part in 
the intervention.  
 
Secondary outcomes 
 
Adherence was measured using the Medication Adherence Rating Scale (MARS; Horne et al., 
2001) which includes five statements scored on a five-point scale from always to never. Four 
items measure intentional non-adherence (e.g. I alter the dose of my tamoxifen tablets), 
with a total score of 20, and one item measures unintentional non-adherence (I forget to 
take my tamoxifen), with a total score of 5. Lower scores indicate more non-adherence.  
 
The scale attempts to mitigate social desirability bias by framing questions in a non-
threatening and non-judgemental way. The scale has demonstrated good internal and test-
retest reliability (Horne et al., 2001) and has been used successfully in breast cancer 
survivors (Cronbach’s alpha=0.68, Grunfeld, Hunter, Sikka & Mittal, 2005). Following 
previous research, women were classified as non-adherent if they scored <25 (Timmers et 
al., 2016; van der Laan et al., 2017). This cut-off helps to counter-balance the over-
estimation of adherence rates (Hüther et al., 2013). Participants also self-reported if they 
had discontinued tamoxifen treatment, and if so, why.  
 
Illness and treatment beliefs were measured using the Beliefs about Medicines 
Questionnaire (BMQ) and the Illness Perceptions Questionnaire for Breast Cancer Survivors 
(IPQ-BCS). The BMQ measures beliefs about the necessity of taking tamoxifen and concerns 
about it (Horne, Weinman, & Hankins, 1999). A differential score was calculated by 
subtracting necessity beliefs from concerns, with higher differential scores indicating a more 
positive cost/benefit analysis. The IPQ-BCS measures the following illness perceptions; 
tamoxifen consequences, breast cancer consequences, cure, risk of recurrence, treatment 
control, personal control, coherence, emotional representations and causal beliefs (Moon, 
Moss-Morris, Hunter & Hughes, 2017a). Each subscale was assessed using four items scored 
on a five-point Likert scale.  
 
Distress was measured using the one factor global distress score of the Hospital Anxiety and 
Depression Scale (HADS; Norton, Cosco, Doyle, Done & Sacker, 2013). Quality of life (QOL) 
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and side-effects were measured using the FACT-ES, a tailored QOL scale for women on HT 
(Fallowfield, Leaity, Howell, Benson & Cella, 1999). An additional concerns subscale lists 
potential side-effects of HT. Additionally, women were asked to rate their confidence in 
managing key symptoms on a 10-point scale ranging from 10 (not confident) to 100 (very 
confident), using a modified version of a standard self-efficacy scale which has been used 
previously in this population (Shelby et al., 2014). The Satisfaction with Information about 
Medicines Scale (SIMS) was used to determine how informed people feel about different 
aspects of their treatment (Horne et al., 2001).  
 
Intervention  
 
Participants completed a four-part self-directed psychoeducational manual. The 
intervention is described in detail elsewhere (Moon, 2017) and its content is summarised in 
Table 1. The intervention consisted of four one-week sections: (1) what is tamoxifen, (2) 
how to take tamoxifen, (3) side-effects of tamoxifen, and (4) support. Participants complete 
a series of CBT-based activities and behaviour change techniques in an accompanying 
activity booklet. Participants were directed to complete SMART (Specific, Measurable, 
Attainable, Relevant and Time-bound) goals in relation to their medication taking and 
symptom management. Intervention materials were accompanied by an explanatory 
telephone call from the researcher. An additional telephone call around two weeks later 
discussed progress and provided assistance with activities. Telephone calls lasted between 
10-20 minutes.  
 
Table 1 about here 
 
Statistical analysis  
 
Based on recommendations for feasibility studies and an expected attrition rate of 20%, the 
desired sample size was 40 participants (Julious, 2005). Statistical analysis was carried out 
using SPSS v21 (SPSS Inc., Chicago, IL). Percentages of women who; i) were eligible to 
participate; ii) consented to participate and; iii) completed follow-up measures were 
calculated. Independent samples t-tests or chi-squared tests were used to compare women 
who completed the study with women who withdrew or were lost to follow-up. Paired 
samples t-tests were used to examine changes over time to study variables. The Wilcoxon 
Signed Rank Test was used to examine changes over time in non-normally distributed data.  
Cohen’s d was calculated to assess the effect sizes based on the mean differences between 
pre- and post-intervention, with the following rules of thumb used to denote small (d=0.2), 
medium (d=0.5) and large (d=0.8) effect sizes. Statistical significance was defined as a two-
tailed p<0.05. Baseline data were carried forward for participants who did not complete 
follow-up questionnaires, and missing item level data were replaced using mean 
substitution. The qualitative interviews were transcribed verbatim and analysed using 
thematic analysis.  
 
Results  
 
Sample Characteristics  
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Participant demographics are shown in Table 2. The mean age was 51 years (SD=6.1, range 
41-68). The majority of women were White British (79%), married or in a Civil Partnership 
(52%) and were employed (89%). Participants were mostly pre or peri-menopausal at 
diagnosis (76%) and had stage I (39%) or stage II (43%) breast cancer. Characteristics were 
similar for those who only completed the baseline questionnaires and those who completed 
the follow-up questionnaires.  
 
Table 2 about here 
 
 
Feasibility: Recruitment and uptake   
 
Figure 1 shows the recruitment and uptake rates across the different recruitment methods. 
Twenty-six eligible women were approached in clinic, of whom twenty consented (77%).  
Invitations were sent to 99 participants from the database, of whom 53 responded (54% 
response rate). Eighteen women were eligible and all consented to participate. Seven 
women responded to the Facebook adverts and three were eligible, all of whom took part in 
the study. The uptake rate across the three recruitment methods was 87%.  
 
[Figure 1 about here] 
 
Feasibility: Retention rates  
 
Retention through the study is also shown in Figure 1. Forty-one women consented, of 
whom eight (20%) did not complete baseline questionnaires or continue with the study. Of 
the 33 women who did complete the baseline questionnaire, 28 completed the intervention 
materials (68% of recruited sample, 85% of those beginning study procedures). Five women 
did not complete the intervention materials, four of whom were lost to follow-up after 
completing the initial telephone call and one who was too busy to participate. Follow-up 
questionnaires were completed by 27 women (66% of total recruited sample, 82% of those 
beginning study procedures). Participants took on average seven weeks (SD=2.6) to 
complete the intervention (range 2-12 weeks).  
 
Independent sample t-tests indicated that women who did not complete the study had 
lower MARS unintentional adherence scores at baseline (M=3.00, SD=0.00) than women 
who did complete the study (M=3.67, SD=0.6, t[26]=5.59, p<.001), indicating more 
unintentional non-adherence. No other significant differences were seen across groups (see 
supplementary material).  
 
Feasibility: Qualitative interviews  
 
The interviews showed that the materials and study procedures were feasible. Some 
participants reported being busy and only engaged with sections which seemed relevant to 
them whereas the majority found it easy to fit into their lives. Most participants found the 
telephone support helpful, but nearly all said they found it easy to work through the manual 
alone. Some participants felt that the intervention would be better suited as a website or 
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app, so they could add things on the go. However, a few women preferred the paper-based 
materials to avoid screen time.  
 
Acceptability: Qualitative interviews  
 
Three themes were identified in the data: satisfaction with materials, areas for 
improvement and the ideal time-point for receiving the intervention. Additional quotations 
in supporti of the themes are included in the online supplementary material.  
 
Satisfaction with materials.  
 
The materials were acceptable, well liked and were viewed as forming a useful resource for 
the future. 
 
“I think it’s amazing and I’m just sad that I didn’t have it when I started because I 
would have found it really, really useful.” Karen, 54  
  
Information about tamoxifen was well received, particularly the diagrams which helped 
women to understand why they were prescribed tamoxifen, how it works and why it is 
important to take it every day.  
 
“That started it off on a real positive for me because I thought; oh I understand now 
what tamoxifen is and what it is for…I thought it was really beneficial..” Kerry, 48  
 
The implementation intentions exercise to pair taking tamoxifen with daily routine was very 
well received by women who did not already have this strategy in place, with women 
describing behaviour changes which had resulted in them remembering to take tamoxifen 
more reliably.  
 
“So, when I’m eating my dinner, then I should just have had my tamoxifen, kind of 
thing.  So that, it definitely helps, definitely missed it less often.” Sharon, 50  
 
Some women also discussed skipping fewer doses now that they understood what 
happened to their bodies when they were not taking it.   
 
“So, there have been occasions when I’ve gone perhaps a week without taking it. I 
don’t think I would do that now. So that’s been good…I just sort of thought, oh it will 
be all right and I hadn’t quite realised fully how it works.” Linda, 67 
 
Participants also found the section on side-effects very helpful. The information on why 
certain side-effects occur and the overview of CBT was well received. Women discussed 
changes to the way they viewed their symptoms.  
 
“I had to stop worrying that I was maybe flustered and actually just breathe through 
it, not focus on it so much, just let it happen. That really worked.” Nancy, 51 
 
Most women also discussed their SMART (Specific, Measurable, Attainable, Relevant, Time-
 8 
based) goals and the strategies they had implemented as a result of the intervention. The 
information about possible side-effects also helped women with feeling less alone.  
 
“So I thought, right I’m getting back to swimming and I’ve been going and I’ve been 
trying to do an extra length each time. So, yes, I have set a goal and I am trying to 
keep to that.” Linda, 67 
 
Areas for improvement. 
  
A few women read the materials but did not complete the activities because they described 
themselves as being “lazy” or because the information was not presented in a learning style 
they felt suited them.  
 
Not all sections of the intervention were relevant to everyone. Some women experienced 
no side-effects or already had strategies for managing them or for remembering to take 
tamoxifen. Section 4 of the intervention booklet on social support was not particularly well 
received, as most people did not need additional support or had already sought it 
themselves.  
 
An important issue to consider was the potential for the information to be distressing or 
upsetting, which led one participant to take a short break from treatment.  
 
“But when I was reading it, I remember being really struck by it.  And I remember 
feeling really quite sad. I’m sure I’ve done enough, four and a half years of taking 
this, I’m stopping.  I did, for three days I didn’t take it, up until my partner found 
out…and now I’ve started taking it again.” Aisha, 46  
 
Ideal time-point for intervention.  
 
Most women said they would like to receive this intervention at the start of their tamoxifen 
prescription as a useful resource to drawn on, even if the booklet was not required straight 
away. However, there was some concern that being shown all of the potential side-effects 
at the start of treatment might be off-putting or worrying to patients and so the 
intervention booklet would be better offered later on.  
 
Secondary outcomes: changes to adherence   
 
Table 3 shows changes to outcome variables over time. The percentage of non-adherent 
women fell from 100% at baseline to 91% at follow-up. The percentage of intentionally non-
adherent women did not change. The percentage of unintentionally non-adherent women 
fell from 97% to 88%, which was reflected by a small improvement (Cohen’s d=0.31) in the 
MARS unintentional scores (p=.058). One woman reported discontinuing treatment during 
the study period on the recommendation of her specialist breast care nurse.  
 
Table 3 here 
 
Secondary outcomes: changes to illness and treatment related outcomes  
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Satisfaction with information about tamoxifen and the necessity/concerns differential 
scores both increased significantly from baseline to follow-up, with a medium effect sizes 
(Table 3). Medium to large effect statistically significant improvements in personal control 
and coherence beliefs were seen. HADS distress scores decreased significantly from pre- to 
post- intervention, but the effect size was small.  
 
Secondary outcomes: changes to side-effect related outcomes  
 
QOL scores improved significantly over time, but the effect size was small. The side-effects 
subscale of the FACT-ES showed that the symptom experience improved significantly over 
time, with a medium effect size (Table 4). 
 
Analyses of self-efficacy for managing symptoms were run only in those women who 
reported experiencing each symptom. Self-efficacy for managing leg cramps/joint pain, 
vaginal health and fatigue all improved significantly with medium effect sizes. There were 
small improvements in self-efficacy for managing hot flushes and changes in mood, but 
these were not statistically significant. When restricting the analysis to only those who 
reported moderate to severe difficulties with each symptom at baseline, medium to large 
significant improvements in self-efficacy were seen for all symptoms.  
 
Table 4 around here 
 
Discussion  
 
This paper has described the initial feasibility and acceptability testing of a 
psychoeducational self-directed intervention for women prescribed tamoxifen. To our 
knowledge, this is the first intervention of its kind. Results showed that the intervention was 
feasible and acceptable and had the potential to improve unintentional non-adherence as 
well as several key variables associated with adherence, such as side-effect management 
and medication beliefs.  
 
These preliminary results suggest that a larger randomised controlled trial (RCT) would be 
feasible in this population. Reasonable response rates were seen from study advertisements 
and uptake from eligible women was high, especially compared with similar self-
management interventions (Bourmaud et al., 2016). However, a large proportion of women 
were ineligible due to high adherence which may present a barrier for future studies. Two 
thirds of the women recruited were retained to the end of the study, with 82% of those who 
received the intervention materials completing the study. However, it should be noted that 
five women (12%) were sent the intervention materials but did not engage with the study.  
 
Women who did not complete the intervention were significantly more non-adherent than 
women who completed the study, suggesting they could have benefited more from the 
intervention. The efficacy of the intervention could have been enhanced if these women 
were included in the full analysis. This is an inherent issue with adherence research and. 
there is a need to investigate ways to engage and retain non-adherent patients in future 
studies. However, the uptake and retention rates here are promising  
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As well as being feasible, the qualitative interviews showed that the intervention materials 
were acceptable. High satisfaction with the intervention was shown, with women changing 
their medication taking behaviour, and implementing strategies to manage side-effects as a 
result. Issues raised included some women not completing the activities, the section on 
social support not being necessary, and the potential for the information to be distressing. 
The interviews also highlighted that not all content was relevant to all women. Whilst this is 
expected, it supports the need for future tailoring of content before embarking on an RCT 
(Lustria et al., 2013).  
 
The study was powered to assess feasibility and acceptability, not efficacy. Despite this, 
some significant changes in key outcomes were seen. Satisfaction with information about 
medication increased significantly with a large effect size. This was highlighted in the 
qualitative interviews, and may be related to the use of diagrams, which many women 
reported increased their understanding of tamoxifen, and have been shown elsewhere to 
reduce dosing errors in those with low health literacy (Yin et al., 2011). An improvement in 
the necessity/concerns differential was also seen, suggesting more favourable evaluation 
towards the necessity of tamoxifen following the intervention. This has important 
implications, as more positive necessity/concerns have been associated with better 
adherence in a number of studies (Brett et al., 2018; Moon, Moss-Morris, Hunter, Norton & 
Hughes, 2018).  
 
Side-effect intensity, QOL, distress, and self-efficacy for managing symptoms improved 
significantly. This is reflected in the qualitative interviews, where women spoke about 
implementing SMART goals and utilising CBT strategies to manage their side-effects. As 
difficulty in managing side-effects, rather than presence or frequency, is more closely 
related to non-adherence, this improved self-efficacy for managing symptoms is particularly 
important (Shelby et al., 2014).  
 
Whilst there were improvements in variables related to adherence, the improvements to 
adherence itself were relatively small. All women were non-adherent at trial 
commencement, and this fell to 91% post-trial. There was a small but non-significant 
improvement in unintentional non-adherence, dropping from 97% to 88%. The qualitative 
interviews suggested this was related to using implementation intentions to pair taking 
tamoxifen with a key daily event. Whilst promising, a large proportion of women remained 
non-adherent after the trial, and rates of intentional non-adherence did not change. This 
may be due to several factors. Firstly, it is likely that the sample were too adherent at 
baseline to detect any improvement. The qualitative interviews showed that the majority of 
women already had good strategies for taking tamoxifen and forgot very rarely, making very 
little room for improvement. Future research may benefit from using a stricter cut off to 
identify sub-optimal non-adherence. Secondly, the measure of non-adherence used may not 
be sensitive to changes over this relatively short follow-up period (Garfield, Clifford, 
Eliasson, Barber, & Willson, 2011). One woman reported reductions in intentional non-
adherence in the qualitative interviews, which were not reflected in the MARS scores. 
Changes to key factors including side-effects and medication beliefs may have a delayed 
effect on improving adherence, as supported by a recent longitudinal analysis (Moon et al., 
2018).  
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Limitations  
 
This was a small study with no control group. Therefore, improvements cannot be 
conclusively attributed to the intervention. As per the MRC framework for developing 
complex interventions (Craig et al., 2008), this successful pilot study demonstrates good 
feasibility and acceptability of the intervention and there is now a need to test the efficacy 
in a full randomised controlled trial. The small sample size prevents sensitivity analyses to 
compare the intervention’s effectiveness across different levels of non-adherence. The 
sample was ethnically homogenous, limiting the generalisability of the results. Additionally, 
women with a diagnosis of depression in the past year were excluded, which may have 
excluded women at higher risk of non-adherence. Due to the convenience sampling method 
adopted, there may be some selection bias in the sample. In addition, only 57% of women 
responded to postal invitations which suggests the sample may not be representative of the 
wider population. Effect sizes were quantified using rules of thumb for Cohen’s d. However, 
these should be interpreted with caution as they do not necessarily indicate whether an 
effect was clinically relevant, and should be considered in relation to similar interventions. 
Adherence was measured using a self-report measure which may over-estimate adherence 
rates and may not provide good concordance with objective measures. Finally, there may be 
a risk of social desirability bias in the qualitative interviews, although attempts were made 
to reduce this by making participants aware the interviewer was independent from the 
intervention.  
 
Clinical Implications  
 
Whilst further testing in an RCT is necessary, the results from this study are promising, 
showing small improvements to adherence and the potential for further improvements by 
modifying several key variables such as medication beliefs and side-effects. Important 
improvements were also seen in distress, side-effect intensity and QOL.  
 
The self-directed nature of the intervention supports broad implementation to large 
numbers of women. The improvements seen to other psychosocial outcomes suggest that 
the intervention could be beneficial for all women prescribed tamoxifen, regardless of 
adherence levels.  
 
Conclusion 
 
To conclude, this intervention appears to be acceptable, feasible and well liked. 
Improvements were seen in adherence, QOL, medication beliefs, distress and confidence in 
managing symptoms. The results improve on previous studies which have seen no changes 
to adherence, perhaps because the intervention addresses several psychosocial constructs 
as well as providing education (Hurtado-de-Mendoza, Cabling, Lobo, Dash, & Sheppard, 
2016). Future research should seek to develop this intervention further, before testing it in a 
full-scale RCT.  
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Table 1. Intervention content  
 
Section  Content covered  
1: What is 
tamoxifen?  
Information on what tamoxifen is, how it works and why women have been 
prescribed it. Additional components: diagrams, videos.  
2: How to take 
tamoxifen  
Information on why it is important to take tamoxifen as prescribed, and what 
happens if you miss doses. Tips for remembering how to take it. Additional 
components: Implementation intentions activity, addressing concerns about 
tamoxifen.  
3: Side-effects of 
tamoxifen  
Tips for managing side-effects, information on understanding links between 
thoughts, feelings and behaviours. Additional components: symptom monitoring, 
SMART goal setting, monitoring progress with goals.  
4: Support  Sources of social support, communicating with healthcare professionals.  
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Table 2. Participant demographics  
 
Completed baseline 
questionnaires (n=33) 
Completed follow- 
up questionnaires 
(n=27)  
Age  M=51, SD= 6.1 (range 
41-68 years) 
M=52, SD=6.3 
(range 42-67)  
Ethnicity  
   White British  
   Other  
   Missing  
 
26 (79%) 
6 (18%) 
1 (3%) 
 
21 (78%) 
5 (19%) 
1 (4%) 
Relationship status  
   Single 
   Married/Civil Partnership  
   Separated/Divorced 
   Co-habiting  
 
6 (18%) 
17 (52%) 
8 (24%) 
2 (6%) 
 
5 (19%) 
16 (59%) 
6 (22%) 
0  
Job status  
   Employed  
   Unemployed  
   Retired  
   Student  
 
29 (89%) 
1 (3%) 
2 (6%) 
1 (3%) 
 
24 (89%) 
1 (4%) 
2 (7%) 
0 
Menopausal status at 
diagnosis  
   Pre/peri-menopausal  
   Post-menopausal  
   Unsure  
 
 
25 (76%) 
6 (18%) 
2 (6%) 
 
 
19 (70%) 
6 (22%) 
2 (7%) 
Breast cancer stage  
   Stage I 
   Stage II 
   Stage III 
 
13 (39%) 
14 (42%) 
6 (18%) 
 
11 (41%) 
12 (44%) 
4 (15%) 
Previous treatment  
   Lumpectomy  
   Single Mastectomy  
   Double Mastectomy  
   Chemotherapy  
   Radiotherapy  
 
20 (61%) 
14 (42%) 
1 (3%) 
19 (58%) 
23 (70%) 
 
17 (63%) 
12 (44%) 
0 
14 (52%) 
17 (63%) 
Years since first prescribed 
tamoxifen  
   <1 year 
   1-2 years 
   2-3 years 
   3-4 years 
   4-5 years 
   >5 years  
 
 
3 (9%) 
9 (27%) 
10 (30%) 
6 (18%) 
3 (9%) 
2 (6%)  
 
 
1 (4%) 
7 (26%) 
10 (37%) 
6 (22%) 
2 (7%) 
1 (4%) 
Note. Percentages may not sum 100 because of rounding.   
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Table 3. Changes to outcome variables over time  
 
Pre 
intervention  
(Mean, SD) 
Post 
intervention  
(Mean, SD) 
Cohen’
s d  
Comparis
on of pre-
and post-
scores   
MARS total 22.8 (1.6) 23.1 (1.3) 0.15 p=.391† 
MARS intentional 19.3 (1.4) 19.4 (1.1) 0.06 p=.786 
MARS unintentional 3.5 (0.6) 3.7 (0.7) 0.31 p=.058† 
% Non-adherent 100% 91% - - 
% Intentionally non-adherent 30% 30% - - 
% Unintentionally non-adherent  97% 88% - - 
Satisfaction with information about treatment   9.42 (4.5)** 11.73 (4.1)** 0.54 p=.003 
Necessity/concerns differential  2.36 (5.2)** 4.76 (5.0) ** 0.47 p=.003 
Cure beliefs  14.61 (2.2) 14.91 (2.6) 0.13 p=.339 
Risk of recurrence beliefs   11.79 (3.6) 10.93 (3.4) -0.17 p=.082 
Tamoxifen consequences 11.97 (4.4) 11.42 (4.0) -0.13 p=.198 
Breast cancer consequences 13.61 (3.2) 13.21 (3.1) -0.13 p=.196 
Personal control 13.85 (2.4) ** 14.88 (2.1) **  0.46 p=.002 
Treatment control 15.24 (2.2) 15.42 (2.0) 0.06 p=.634 
Coherence 13.88 (3.7) 
*** 
16.51 (2.7) 
*** 
0.58 p<.001 
Emotional representations 14.36 (4.0) 14.33 (4.3) -0.01 p=.953 
Distress  14.60 (8.6) ** 12.58 (7.7) ** -0.25 p=.002 
Note. †Indicates that Wilcoxin Signed Ranks Test was used to compare means.  * Indicates a 
significant difference at p<0.05, ** indicates a significant difference at p<0.01. Scores of 25 on the 
MARS indicate total adherence. Scores of 20 indicate full intentional adherence. Scores of 5 indicate 
full unintentional adherence. 
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Table 4. Changes to side-effect related outcomes over time  
 
Pre 
intervention  
(Mean, SD) 
Post 
intervention  
(Mean, SD) 
Cohen’
s d  
Comparis
on of pre-
and post-
scores   
Quality of life total 122.90 
(28.1)** 
130.03 (25.4) 
** 
0.26 p=.003 
FACT-ES Symptom score  48.54 (13.2) 
*** 
55.33 (11.44) 
*** 
0.54 p<.001 
Satisfaction with information about treatment   9.42 (4.5)** 11.73 (4.1)** 0.54 p=.003 
Self-efficacy for managing hot flushes      
       In those with hot flushes (n=30) 68.33 (25.5) 73.67 (21.9) 0.23 p=.084 
       In those with moderate/severe hot flushes (n=18) 56.67 (24.5)* 66.67 (22.8)* 0.42 p=.027 
Self-efficacy for managing night sweats      
       In those with night sweats (n=26) 65.38 (26.9) 68.46 (20.9) 0.13 p=.448 
       In those with moderate/severe night sweats (n=19) 57.89 (26.2)* 65.79 (22.4)* 0.32 p=.043 
Self-efficacy for managing leg cramps / joint pain     
       In those with leg cramps / joint pain (n=28) 58.21 (23.4)* 68.21 (23.4)* 0.42 p=.039  
       In those with moderate/severe leg cramps/joint 
pain (n=17) 
50.00 
(24.3)** 
63.5 (28.5)** 0.51 p=.007 
Self-efficacy for managing vaginal health related 
problems   
    
       In those with vaginal health related problems 
(n=31) 
61.29 
(26.4)** 
72.58 
(22.3)** 
0.46 p=.002 
       In those with moderate/severe vaginal health 
related problems (n=23) 
56.52 (24.2) 
** 
67.39 (22.0) 
** 
0.47 p=.005 
Self-efficacy for managing mood changes       
      In those with mood changes (n=26) 45.39 (28.7) 51.92 (26.8) 0.24 p=.134 
      In those with moderate/severe symptoms (n=18) 35.56 (23.1) 
** 
47.22 
(25.9)** 
0.48 p=.008 
Self-efficacy for managing fatigue (n=18) 53.33 
(25.7)** 
67.22 
(27.0)** 
0.53 p=.001 
Self-efficacy for managing insomnia (n=17) 53.89 (26.2) 57.78 (25.1) 0.15 p=.360 
Note. * Indicates a significant difference at p<0.05, ** indicates a significant difference at p<0.01. 
Higher FACT-ES symptom scores indicate reduced impact of side-effects. Data on severity of 
insomnia / fatigue is missing. 
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Figure 1. Recruitment, uptake and retention.  
DCIS=Ductal Carcinoma in Situ  
Completed baseline questionnaires (n=33) 
Did not complete baseline questionnaires (n=8) 
• No longer wants to participate (n=1) 
• Stressful life events (n=1) 
• No response (n=6) 
 
Completed intervention materials (n=28) 
Did not complete intervention materials (n=5) 
• Too busy (n=2) 
• Other stressful life events (n=1) 
• No response (n=2) 
 
 
Did not compete follow up questionnaire (n=1) 
 
Approached in clinic (n=158) Invites sent to participants in previous 
database (n=99) 
Responded (n=53) 
Eligible (n=26) 
Not eligible (n=132) 
• DCIS/metastatic cancer (n=5) 
• Adherent (n=86) 
• Learning difficulties, 
language barrier, dementia 
(n=17) 
• Stopping tamoxifen soon 
(n=13) 
• Unknown (n=2) 
• Depression (n=5) 
• Not interested in research 
(n=4) 
 
Consented (n=20) 
Not consented (n=6) 
• Patient not interested (n=1) 
• Patient too busy (n=2) 
• Unknown (n=3) 
Not eligible (n=35) 
• Not on tamoxifen (n=5) 
• DCIS (n=4) 
• Adherent (n=12) 
• Depression (n=5) 
• Learning difficulties, language 
barrier, dementia (n=1) 
• Stopping tamoxifen soon 
(n=5) 
• Not interested in research 
(n=2) 
• Patient deceased (n=1) 
 
 
No response (n=46) 
 
Eligible (n=18) 
Consented (n=18) 
Completed follow up questionnaire (n=27) 
Consented (n=41) 
Responded to 
Facebook adverts 
(n=7) 
Not eligible (n=4) 
• Adherent (n=4) 
 
 
Eligible (n=3) 
Consented (n=3) 
